[A21-121] Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V
Last updated 16.02.2022
Project no.:
A21-121
Commission:
Commission awarded on 16.09.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Patients with active polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), 2 years of age and older, who have responded inadequately to previous therapy with disease-modifying antirheumatic drugs (DMARDs)
- pJIA, inadequate response to previous therapy with conventional DMARDs (including MTX): added benefit not proven.
- pJIA, inadequate response to previous therapy with one or several biologic DMARDs: added benefit not proven.
- jPsA, inadequate response to previous therapy with one or several DMARDs: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 2022-12-15.
| Project no. | Title | Status |
|---|---|---|
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-18 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A21-165 | Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |